Lower GI 2017

Disease-free Survival

Absolute Difference

Colon Cancer Stage II/III

n

HR P-value

5% (3y)

MOSAIC

2246

0.77 .002

4% (3y)

NSABP C-07

2407

0.80 .003

Rectal Cancer Stage II/III Neoadjuvant oxaliplatin

4.3% (5y)

ACCORD 12

584

0.86 0.25

5% (5y)

NSAPB R-04

1284

0.91 0.34

4.7% (3y)

CAO/ARO/AIO-04

1236

0.79 0.03

10.6% (3y)

Chinese

206

n.g.

0.08

STAR-01 and full paper of PETACC-6 pending